Clinical Trial Detail

NCT ID NCT01274624
Title Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Oncolytics Biotech

colon cancer

rectum cancer


Fluorouracil + Irinotecan + Leucovorin

Bevacizumab + Pelareorep

Age Groups: adult

No variant requirements are available.